BeiGene Ltd
BGNE
ISIN null / Valor 30165310
BeiGene Ltd
UMushroom community rating:
About company
BeiGene Ltd is a Beijing‑founded, research‑driven biopharmaceutical company that develops, manufactures and commercializes cancer treatments worldwide. The company concentrates on oncology, advancing a pipeline of targeted small molecules, monoclonal antibodies and other immuno‑oncology assets through global clinical trials while building commercial operations in major markets including China, the United States and Europe. Its marketed products include the BTK inhibitor zanubrutinib and the anti‑PD‑1 antibody tislelizumab, and it pursues both in‑house development and collaborations to expand indications and geographic reach. BeiGene is vertically integrated across discovery, development and production capacities and is publicly traded on U.S. and Hong Kong exchanges.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
32473 M
Market cap (USD)
159,376
Daily traded volume (Shares)
185.01 / 179.74
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Christian Bircher
EQUITIES OF THE SAME SECTOR
